In vivo preclinical efficacy of MGD014 and MGD020 (HIV-1 envelope x CD3 DART molecules) and first-in-human phase 1 clinical safety evaluation of MGD014

被引：0
|
作者：
Nordstrom, J. L. [1 ]
Gay, C. L. [2 ,3 ]
Bohac, C. [1 ]
Wahl, A. R. [4 ,5 ]
Morgan, T. [4 ,5 ]
Schmitz, J. L. [6 ]
Li, H. [1 ]
Cotshott, J. [1 ]
Gobburu, J. [7 ,8 ]
Macintyre, A. N. [9 ,10 ]
Gorelick, R. J. [11 ]
Ferrari, G. [12 ,13 ]
Margolis, D. M. [2 ,3 ]
Garcia, J. V. [4 ,5 ]
机构：
[1] MacroGenics Inc, Rockville, MD USA
[2] Univ North Carolina Chapel Hill, Sch Med, UNC HIV Cure Ctr, Chapel Hill, NC USA
[3] Univ North Carolina Chapel Hill, Dept Med, Chapel Hill, NC USA
[4] Univ North Carolina Chapel Hill, Int Ctr Adv Translat Sci, Div Infect Dis, Chapel Hill, NC USA
[5] Univ North Carolina Chapel Hill, Ctr AIDS Res, Chapel Hill, NC USA
[6] Univ North Carolina Chapel Hill, Sch Med, Dept Pathol & Lab Med, Chapel Hill, NC USA
[7] Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA
[8] Univ Maryland, Sch Med, Baltimore, MD 21201 USA
[9] Duke Univ, Sch Med, Durham, NC 27706 USA
[10] Duke Human Vaccine Inst, Durham, NC USA
[11] Leidos Biomed Res Inc, AIDS & Canc Virus Program, Frederick, MD USA
[12] Duke Univ, Dept Surg, Durham, NC 27706 USA
[13] Duke Univ, Dept Mol Genet & Microbiol, Durham, NC 27706 USA
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2022年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
OAA0403
引用
收藏
页码：6 / 7
页数：2
相关论文
共 5 条
  • [1] A phase I, first-in-human study of MGD006/S80880 (CD123 x CD3 DART) in AML/MDS.
    Vey, Norbert
    Davidson-Moncada, Jan Kenneth
    Uy, Geoffrey L.
    Rizzieri, David
    Khoury, Hanna Jean
    Foster, Matthew Charles
    Godwin, John E.
    Topp, Max S.
    Martinelli, Giovanni
    Ciceri, Fabio
    Carrabba, Matteo Giovanni
    Huls, Gerwin A.
    Wegener, Antje
    Tran, Kathy C.
    Shannon, Michele
    Sun, Jichao
    Wigginton, Jon M.
    DiPersio, John F.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] A Phase 1, First-in-Human, Dose-Escalation Study of MGD024, a CD123 x CD3 Bispecific Dart® Molecule, in Patients with Relapsed or Refractory CD123-Positive (+) Hematologic Malignancies
    Winer, Eric S.
    Maris, Michael
    Sharma, Manish R.
    Kaminker, Patrick
    Zhao, Enxu
    Ward, Ashley
    Sochacki, Andrew L.
    BLOOD, 2022, 140 : 11753 - 11754
  • [3] A phase 1, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 x CD3 DART molecule, in patients with relapsed/refractory metastatic colorectal carcinoma
    Powderly, John D.
    Hurwitz, Herbert
    Ryan, David P.
    Laheru, Daniel A.
    Pandya, Naimish B.
    Lohr, Joanna
    Moore, Paul A.
    Bonvini, Ezio
    Wigginton, Jon M.
    Crocenzi, Todd S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Phase 1, first-in-human, open label, dose escalation ctudy of MGD009, a humanized B7-H3 x CD3 dual-affinity re-targeting (DART) protein in patients with B7-H3-expressing neoplasms or B7-H3 expressing tumor vasculature
    Tolcher, Anthony W.
    Alley, Evan W.
    Chichili, Guru
    Baughman, Jan E.
    Moore, Paul A.
    Bonvini, Ezio
    Vasselli, James Robert
    Wigginton, Jon M.
    Powderly, John D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] Updated Safety and Efficacy Results of Abbv-383, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in a First-in-Human Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma
    Vij, Ravi
    Kumar, Shaji Kunnathu
    D'Souza, Anita
    Mckay, John T.
    Voorhees, Peter M.
    Chung, Alfred
    Tuchman, Sascha Alexander
    Korde, Neha
    Weisel, Katja
    Teipel, Raphael
    Bueno, Orlando
    Feng, Zhongling
    Rosenberg, Tanya S.
    Pothacamury, Rajvineeth Kumar
    Polepally, Akshanth R.
    Lee, Shane
    Jin, Ziyi
    Ross, Jeremy A.
    Ahsan, Aarif
    Talati, Chetasi
    Rodriguez, Cesar
    BLOOD, 2023, 142
1